← Leaderboards
Andrew Loring Schilb
Janusq, Llc
$1,567,687
Attributed
$1,567,687
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,567,687 · 4
By mechanism
R43$1,567,687 · 4
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposNeurotoxicityFunctional DisorderMitochondriaNervous System DisorderNeuronsMedicalIn VivoDoseMedical Care CostsGrantFutureNeurodegenerative DisordersBehavioralMitochondrial DysfunctionClinicCommercial ApplicationCommercializationCaregiversBiotechnologyDrug KineticsBrain TissueBrainNovel Therapeutics
Grant awards (4)
Pharmacokinetics and in vivo efficacy of DA1 macrocyclic peptides in a murine model of Alzheimer's disease$576,664
R43 · FY2025 · AG · contact PI
In vivo efficacy and in vitro toxicity assessment of peptide-based therapy HV-3 for the Treatment of Huntington's disease$490,501
R43 · FY2025 · NS · contact PI
Pharmacokinetic and pharmacodynamic assessment of peptide-based therapy DA1 for the treatment of Alzheimer's disease$259,584
R43 · FY2022 · AG · contact PI
Pharmacokinetic Assessment of Peptide-Based Therapy HV-3 for the Treatment of Huntington's Disease$240,938
R43 · FY2021 · NS · contact PI